This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172–183.
Druker BJ, Guilhot F, O’Brien SJ, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.
Hochhaus A, Kreil S, Corbin AS, La Rosée P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.
Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.
Vigneri P, Wang JY . Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228–234.
Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP et al. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 2006; 107: 1591–1598.
Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96: 9112–9117.
Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmier AM, Bühring HJ et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004; 103: 523–529.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allan, E., Hamilton, A., Hatziieremia, S. et al. Nuclear entrapment of BCR–ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells. Leukemia 23, 1006–1008 (2009). https://doi.org/10.1038/leu.2008.367
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.367